Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook

Go back to Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook

Biogen (BIIB) Pushes Higher Following EPS

January 27, 2016 11:55 AM EST

Biogen (NASDAQ: BIIB) is pushing to the highs of the session following strong earnings and a solid outlook. Shares are now up 7.9%

... More

Biogen (BIIB) Tops Q4 EPS by 42c; Guides In-Line

January 27, 2016 7:16 AM EST

Biogen (NASDAQ: BIIB) reported Q4 EPS of $4.50, $0.42 better than the analyst estimate of $4.08. Revenue for the quarter came in at $2.84 billion versus the consensus estimate of $2.71 billion.

GUIDANCE:

Biogen sees FY2016 EPS of $18.30-$18.60, versus the consensus of $18.45. Biogen sees FY2016 revenue of $11.1-11.3 billion, versus the consensus of $11.29 billion.

We saw solid performance in our industry leading multiple sclerosis portfolio and strong... More